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Introduction
The Draize eye irritation test is used to evaluate the
hazard from a single exposure of the eye to chemi-
cals that result in lesions, and has been required by
official guidelines for evaluation of biomedical
devices and cosmetics (1). Up to now, it has been
considered to be the gold standard in toxicological
evaluations of the effects of chemicals on the eye,
but it is criticised because it uses a scoring system
based on subjective observations. The results of
many in vivo studies have been collected in data-
bases, including an ECETOC report (2). 
The ideal ‘modern’ methodological approach is to
avoid animal experiments altogether, which is cur-
rently best achieved by using the biomathematical
models proposed by Prospisil et al. (3), but it has not
yet been possible to replace the rabbit eye test with
in vitro methods. A number of new approaches have
been submitted to ECVAM and ICVAM for app -
roval. Van Goethem et al. (4) have published details
of a test involving corneal constructs as one prom-
ising possibility. However, such constructs do not
reflect the mechanical structure and diffusion
mechanisms of the living cornea. Furthermore, the
transfer of endothelium to the model and its subse-
quent maintenance are still unresolved issues, since
the outcome depends strongly on the origin of the
tissues, the method of immortalisation, and the
cyclic age of the cultures. The standardisation of
culture conditions, serum supplies, and many other
factors are also regarded as problematic issues,
which may affect the predictive value of results (5).
Therefore, our goal was to develop a reliable irri-
tation testing system, based on highly-standardised
corneal cultures of the type routinely used during
organ culture for subsequent transplantation.
There is considerable knowledge of the metabolic
equilibrium of such corneas within this culture sys-
tem (6), and the rabbit eye is the most widely stud-
ied medical model in corneal research. We therefore
standardised the culture method normally used for
corneal organ culture, and developed determinants
of irritation analysis within this new system, which
are more objective than those that are currently
used in the Draize model (1).
We were interested in demonstrating the reliabil-
ity of our system, the Ex Vivo Eye Irritation Test
(EVEIT), and in investigating whether benzalko-
nium chloride (BAC) could be identified as toxic, as
determined by inhibition of epithelial recovery. We
used repeated exposure to BAC, with subsequent
monitoring of wound healing and assessment of the
metabolic status of the cornea. In addition, we
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addressed the key issues in efforts to reduce, refine
and, finally, replace animal experiments (the Three
Rs), in order to establish the EVEIT as a reliable
method for the prediction of relevant effects on the
cornea in a short-term experimental set-up.
Materials and Methods
The EVEIT
The EVEIT uses only corneas that are freshly-
obtained from the slaughter house, which involves a
delay of up to eight hours prior to preparation for use.
In the development of the method, the eyes were
transported in complete heads cooled to 4°C. The lids
were briefly opened and Polyspectran® eye drops (Dr
Thilo GmbH & Co. KG, Freiburg, Germany) were
applied into the conjunctival sac before transporta-
tion. Subsequently, the corneas were excised from the
eyes with a 12mm trephine, and the adhering tissues
were gently removed. Each isolated cornea, with
about 2mm of adherent sclera, was placed in a special
corneal culture chamber (ACTO e.V., Aachen,
Germany), clamped between the upper and lower
parts of the perfusion chamber. After the placement of
the cornea, the chamber was gently filled with perfu-
sion medium (Minimum Essential Medium [MEM],
Cat. No. T031-05, Biochrom AG, Berlin, Germany),
with added piperacillin (2mg/ml; Ratiopharm GmbH,
Ulm, Germany), amikacin (0.2mg/ml; Fresenius Kabi
Deutschland GmbH, Bad Homburg von der Höhe,
Germany), and nystatin (400U/ml; Valeant Pharm -
aceuticals Germany GmbH, Eschborn, Germany).
The medium was constantly replenished by using a
micropumping system, with an entrance pH of 7.4 ±
0.2 and a flow rate of 6µl/min. The chambers were
maintained at 32°C in normal air and 100% relative
humidity for 24 hours, prior to the use of the
explanted corneas.
Quality control
After stabilisation for 24 hours in the EVEIT culture
system, the epithelial integrity of the corneas was
verified with fluorescein surface staining (1.7mg/ml
fluorescein, sodium salt; Sigma–Aldrich, St. Louis,
MO, USA), an assessment of the endothelial appear-
ance from the back of the chamber, and the determi-
nation of lactate production, to ensure that the
conditions for testing were standardised. If lactate
production was lower than 1mmol/l, the endothelium
showed obvious cell loss, or the epithelium exhibited
fluorescein-positive regions, then the cornea con-
cerned was excluded from further processing.
Examination techniques
The epithelial surface was examined microscopically.
The surface was stained with fluorescein, and images
were taken by using a Canon EOS 500 digital camera
with a macro-lens (Canon, Inc., Tokyo, Japan).
Samples of medium from the artificial anterior cham-
ber outflow were taken continuously. After each hour
(i.e. 360µl total volume), the samples were analysed
for glucose, lactate and pH (Bayer Automatic
Analyser: Rapid Lab 860; Siemens Diagnostics,
Fernwald, Germany).
Mechanical abrasion
A small dental drill (Arkansasschleifer 638XF,
Meisinger, Neuss, Germany) was used to create four
small abrasions on the cornea, each with an area of
0.3–0.6mm2. All defects were stained daily with fluo-
rescein, briefly flushed after three seconds with iso-
tonic Ringer’s solution (DeltaSelect GmbH,
Pfullingen, Germany) to remove excess fluorescein,
and then photographed immediately. The yellow
green fluorescence in Figure 1 indicates epithelial
defects, initially due to mechanical abrasion, and, in
the later stages of the experiment, due to the local
toxicity of the applied substances.
Application of test substances
Unpreserved hyaluronate citrate drops (HYLO-
LASOP®, Ursapharm Arzneimittel GmbH & Co.
KG, Saarbrücken, Ger many) and an artificial tear
replacement (a physiological saline solution con-
taining 14.581 mmol Ca2+ in 0.9% saline solution;
DeltaSelect GmbH), with or without 0.001–0.1%
BAC (w/v; Sigma-Aldrich Chemie GmbH, Munich,
Germany), were applied by using two separate
dropping devices, exactly over the apex of the
cornea. A 20µl drop of each solution was applied
hourly, with a maximum time difference of 30 min-
utes between application of the test substances and
the artificial tears. In terms of ‘real-life’ simulation,
this test offers the opportunity to ascertain the
effects of hourly applications of a drug, as would be
utilised in a therapeutic regime. Higher frequencies
of application would not be indicative of the ‘real-
life’ clinical application of the drug. Eye drops were
not applied simultaneously, on any occasion. A soft-
tipped cannula, applying continuous suction, was
placed on the lower side of the cornea in culture to
remove excess fluid.
Negative controls were represented by two
corneas, with four small abrasion sites on each,
treated with MEM and artificial tear replacement
24 times per day (once per hour). Excess fluids were
again removed by suction with a soft-tipped can-
nula, placed on the lower part of the anterior
cornea. A further set of two intact corneas were
used as control for vitality and integrity of the
epithelium within the test system (i.e. no abrasions
were made, and no test substances were applied).
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Results
The vitality controls, with no initial erosion,
remained clear and showed no corneal opacity
throughout the experimental period of four days
(Figure 2). The negative controls treated with MEM
showed considerable, but incomplete, healing
(Figure 3); at day 4, corneal erosion was still evi-
dent, with a slight greyish appearance of the ero-
sion and epithelial edges. Figure 4 shows corneas
treated with hyaluronate citrate and artificial tears.
The complete healing of the epithelial defects is
clearly visible. A trace of fluorescein staining at the
former centre of the epithelial defects was scarcely
visible after four days.
Figures 5a–5e show corneas treated with
hyaluronate citrate and artificial tears containing
different concentrations of BAC. Dose-dependent
swelling, with corneal stromal opacity, roughness of
the epithelium, and disintegration of the epithelial
surface at the highest concentrations, was
observed. The acceleration of the damage to full
necrosis, together with metabolic failure (as evi-
denced by the absence of lactate production), was
clearly dependent on the BAC concentration
(Figure 6).
Corneas treated with 24 drops per day (once per
hour) of hyaluronate citrate and calcium-containing
artificial tears with 0.001% BAC, showed damaged
surface integrity, and no healing of the initial ero-
sion was apparent (Figure 5a). The lactate concen-
tration (Figure 6) remained in the expected range,
showing that the tissue would still be able to
recover and re-epithelialise, if the treatment with
the toxic substance was stopped.
Increasing the concentration of BAC to 0.01% led
to marked destruction of the epithelium, with
extensive corneal erosion (Figure 5b). With 0.025%
BAC, the visible damage (Figure 5c) appeared
almost the same as that which occurred with 0.01%
BAC. However, lactate production by the 0.025%
BAC-treated tissues was clearly impaired much ear-
lier than it was with the lower concentration,
decreasing to almost complete metabolic failure at
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Figure 1: A macroscopic photograph of a
cornea within the EVEIT, with four
corneal abrasions stained with
fluorescein
Figure 2: A cornea within the EVEIT, serving as a vitality control
The images show the isolated cornea a) at the beginning (Day 0) and b) at the end (Day 4) of the experiment.
a) b)
Figure 3: A cornea within the EVEIT, treated with repeated drops of MEM
MEM was added at the rate of 1 drop per hour. The images show the isolated cornea a) at the beginning (Day 0) and b)
at the end (Day 4) of the experiment.
a) b)
the end of the experiment. Further increasing the
concentration of BAC to 0.05% and 0.1% led to
increasingly-worse lesions and partially stripped-off
epithelia, with stromal deformation and full necro-
sis (Figures 5d and 5e).
The correlation of these adverse effects with BAC
concentration is clear from Figure 6. At 0.1%, BAC
caused the almost immediate destruction of the tis-
sue, and no lactate production was detectable from
the third day of the experiment. This, together with
the visible degradation of the cornea, indicated the
complete death of all cellular material.
Figure 4: A cornea within the EVEIT, treated with hyaluronate citrate drops and artificial
tears
Hyaluronate citrate and artificial tears were added at the rate of 1 drop per hour. The images show the isolated cornea
a) at the beginning (Day 0) and b) at the end (Day 4) of the experiment.
a) b)
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Figure 5: Corneas within the EVEIT, treated with hyaluronate citrate drops and artificial
tears containing a range of BAC concentrations
Hyaluronate citrate and artificial tears, with different BAC concentrations, were added at the rate of 1 drop per hour.
Photographs were taken after a 4-day treatment.
a) 0.001% BAC b) 0.01% BAC
c) 0.025% BAC d) 0.05% BAC
e) 0.1% BAC
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Discussion
Previous studies have confirmed that BAC in eye
drops improves penetration (7), is toxic upon single
application (8), more toxic upon multiple applica-
tions (9), and may cause damage at very low con-
centrations (10), at least to the epithelial layer of
the cornea (9). The results from the present study
confirm the morphological changes that have been
previously observed by others upon fluorescein-
staining of the cornea in humans and in rats to
determine morphological damage (9, 10). Imayasu
et al. (11) reported severe damage to rabbit eyes
from BAC exposure, reflected by lactate dehydroge-
nase (LDH) release from corneas in vivo. This cor-
relates with the results from our lactate
determinations, which, in contrast to the use of
cytosolic LDH release as the classic indicator of
membrane defects, directly reflect the breakdown
of metabolic activity within the cells. LDH as
marker of cellular integrity, and lactate as marker
of cellular metabolic activity, are closely related to
the vitality of the corneal tissue. The dose-depend-
ent impairment of lactate production during
repeated BAC exposure is a clear and simple indica-
tor of cellular damage, which is less susceptible to
measurement errors than is the LDH assay.
There is clear evidence that the results obtained
with the EVEIT model, presented here in the spe-
cific case of BAC exposure, correlated well with the
morphological findings observed in humans (9), in
all the types of experimental animal cell lines stud-
ied (12), and with excised isolated corneas from
goat, sheep and buffalo (7). Multiple exposures over
several days, with the possibility of surviving tissue
and ongoing damage assessment, are the excep-
tional advantages of our method that have so far
only been achieved with live animals. By specific
determination of the extent of healing after corneal
mechanical trauma, during the concurrent repeated
exposure to BAC and non-irritants, we were able to
demonstrate that the EVEIT is a good predictor of
the dose-dependent toxicity in this specific case.
Further experiments are soon to be published, to
confirm the suitability of the EVEIT model for the
testing of other chemicals.
We observed different stages of corneal healing
after different types of repeated application, and a
direct effect on the vitality status of the cornea. The
EVEIT system showed that after deliberate dam-
age, citrate-buffered hyaluronate drops improved
epithelial healing, with a constant rate of epithelial
closure, even with larger corneal defects. The
EVEIT was able to identify the toxic effects of dif-
ferent concentrations of BAC, in a model that is
both time-efficient and, more importantly, does not
require the use of animals specifically obtained for
this purpose. This replacement of animals by the
EVEIT was fundamental to the achievement of one
of the major targets of the project, that it should
support the principles of the Three Rs (reduction,
refinement and replacement).
We are convinced that the EVEIT is a promising
candidate for replacing the Draize test in pharma-
ceutical research on the cornea, and that it could be
used as a possible eye-irritation test within the
framework of the REACH initiative on chemicals. 
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